European Society of Hematology

June 2009
BioWorld Today;6/9/2009, Vol. 20 Issue 109, p5
The article reports on the results of a study which compared Nplat or romiplostim to the medical standard of care in nonsplenoctomized adult patients with chronic immune thrombocytopenic purpura (ITP), released by Amgen Inc. Results revealed that Nplat substantially decreased the incidences of splenectomy and treatment failures in nonsplenoctomized adults patients with chronic ITP.


Related Articles

  • Eltrombopag Tablets (Promacta). Elliot, William T.; Chan, James // Internal Medicine Alert;3/15/2009, Vol. 31 Issue 5, p37 

    The article presents a drug study of Eltrombopag Tablets (Promacta), a thrombopoietin (TPO) receptor agonist. The drug is intended for thrombocytopenia in patients associated with chronic immune (idiopathic) thrombocytopenia purpura. Moreover, it also provides the drug's dosage, potential...

  • Romiplostim. Cines, Douglas B.; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Nov2008, Vol. 7 Issue 11, p887 

    In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

  • Immune Thrombocytopenia in Tuberculosis: Causal or Coincidental? Gopalakrishnan Srividya; Gopalakrishna Pillai Syamala Nikhila; Kaushik, Adusumilli Venkatakrishna; Jayachandran, Kuppusamy // Journal of Global Infectious Diseases;Jul-Sep2014, Vol. 6 Issue 3, p128 

    Immune thrombocytopenia is a relatively rare hematological manifestation in tuberculosis. We report two cases of immune thrombocytopemia, one in sputum positive pulmonary tuberculosis and the other in miliary tuberculosis. Antituberculous drugs and immunosuppressive therapy corrected the...

  • News from EHA.  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p4 

    The article features several studies presented at the 17th Congress of the European Haematology Association (EHA) in Amsterdam, the Netherlands. A research found that romiplostim is cost effective in treating patients with immune thrombocytopenia purpura (ITP) in Ireland. Another study revealed...

  • In the pipeline: Novel treatments for chronic ITP on horizon. Belden, Heidi // Drug Topics;5/12/2008, Vol. 152 Issue 6, p24 

    The article reports on developments in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). It is said that GlaxoSmithKline (GSK) has filed a new drug application for eltrompobag, which, according to the company, will be a short-term treatment for patients who have previously been...

  • Platelet stimulation to treat adults with chronic immune thrombocytopenic purpura.  // British Journal of Hospital Medicine (17508460);Nov2009, Vol. 70 Issue 11, p616 

    The article reports on the treatment of chronic immune thrombocytopenic purpura with Nplate (romiplostin) developed by Amgen Inc. in Great Britain. It is noted that the mechanism of action of romiplostin is same as with thrombopoetin which increases platelet production to prevent bleeding....

  • New biologic.  // Formulary;Oct2008, Vol. 43 Issue 10, p354 

    The article discusses the approved thrombopoietin mimetic peptibody for treating chronic immune thrombocytopenic purpura (ITP), Romiplostim, from Amgen Inc. According to the author, the said peptibody increases platelet production and is approved by the Food and Drug Administration. Efficacy and...

  • Management of Immune Thrombocytopenia � Something Old, Something New. George, James N. // New England Journal of Medicine;11/11/2010, Vol. 363 Issue 20, p1959 

    The author discusses the results of a study on the management of immune thrombocytopenia, featured in the November 2010 issue of the "New England Journal of Medicine." He mentions how he has witnessed the evolution of the management of immune thrombocytopenia from clinical experience instead of...

  • Hospital costs can take a HIT in Germany.  // PharmacoEconomics & Outcomes News;6/27/2009, Issue 581, p6 

    The article discusses research on the hospitalization costs of treating heparin-induced thrombocytopenia (HIT). It references a study by T. Wilke and colleagues published in the May 2009 issue of the "Journal of Thrombosis and Haemostasis." Researchers found the mean cost per person of HIT to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics